| Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. | |
| | |
MedLine Citation:
|
PMID: 16735672 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin. METHODS AND RESULTS: We examined prescription patterns and outcomes (all-cause mortality and/or HF readmission) in patients discharged from 103 Canadian hospitals between April 1999 and March 2001 after a first hospitalization for HF. Of 7352 patients with HF (mean age, 75 years; 44% without coronary disease and 29% with renal dysfunction), 2785 (38%) died or required HF readmission within the first year. Compared with nonusers, aspirin users were no more likely to die or require HF readmission (hazard ratio [HR], 1.02 [0.91 to 1.16]), even in patients without coronary disease (HR, 0.98 [0.78 to 1.22]) or patients with renal dysfunction (HR, 1.13 [0.94 to 1.36]). On the other hand, users of ACE inhibitors were less likely to die or require HF readmission (HR, 0.87 [0.79 to 0.96]), even if they were using aspirin (HR, 0.86 [0.77 to 0.95]). There were no dose-dependent interactions between aspirin and ACE inhibitors. CONCLUSIONS: In this observational study, aspirin use was not associated with an increase in mortality rates or HF readmission rates, and aspirin did not attenuate the benefits of ACE inhibitors, even in patients without coronary disease, patients with renal dysfunction, or patients treated with high-dose aspirin and low-dose ACE inhibitors. |
| | |
Authors:
|
Finlay A McAlister; William A Ghali; Yanyan Gong; Jiming Fang; Paul W Armstrong; Jack V Tu |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2006-05-30 |
Journal Detail:
|
Title: Circulation Volume: 113 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2006 Jun |
Date Detail:
|
Created Date: 2006-06-06 Completed Date: 2006-06-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 2572-8 Citation Subset: AIM; IM |
Affiliation:
|
Division of General Internal Medicine, University of Alberta, Edmonton, Canada. Finlay.McAlister@ualberta.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiotensin-Converting Enzyme Inhibitors / pharmacology*, therapeutic use Anti-Inflammatory Agents, Non-Steroidal / adverse effects*, pharmacology Aspirin / adverse effects*, pharmacology Cohort Studies Coronary Disease / complications, physiopathology Dose-Response Relationship, Drug Drug Interactions Drug Therapy, Combination Drug Toxicity Female Heart Failure / complications, drug therapy*, mortality Hemodynamics / drug effects, physiology Humans Kidney Diseases / complications, physiopathology Male Middle Aged Multivariate Analysis Odds Ratio Patient Readmission / statistics & numerical data Prognosis Proportional Hazards Models Prospective Studies Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Inflammatory Agents, Non-Steroidal; 50-78-2/Aspirin |
| Comments/Corrections | |
Comment In:
|
Circulation. 2006 Jun 6;113(22):2566-8
[PMID:
16754810
]
Circulation. 2007 Jan 30;115(4):e54; author reply e55 [PMID: 17261667 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rituximab in the treatment of acquired hemophilia.
Next Document: Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.